Aventis/Dermik’s Facial Repair Device Gets Compassionate Panel Nod
This article was originally published in The Gray Sheet
Executive Summary
FDA should actively restrict access to Aventis/Dermik Labs' Sculptra injectable facial restoration agent to patients with HIV-related lipoatrophy, according to FDA's General & Plastic Surgery Devices Panel